Trial Profile
Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Mar 2018
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary)
- Indications Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Johnson & Johnson
- 01 Feb 2018 Results published in the Hematological Oncology
- 27 May 2016 Status changed from recruiting to completed.
- 11 Feb 2015 Planned End Date changed from 1 Oct 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.